Pluristem has offices in the USA.

These forward looking statements are based on current expectations of the management of Pluristem is based, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Legislative changesing factors could include the actual results described materially from those in the forward-looking statements: catch missing necessary regulatory approvals, changes in technology and market requirements, our technology is not confirmed, we and and progress our methods not by the scientific community accepted, we can not get in a position or attract key employees whose knowledge is essential to the development of our products; develop to unforeseen scientific difficulties develop with our process, can results in the laboratory does not equal good results translate into real surgical settings; our patents not possibly be sufficient, our products may harm recipients; legislative changes, inability to timely develop and introduce new technologies, products and applications; cause loss of market share and pressure on prices from competition, which could cause actual results or performance of Pluristem to differ materially from those that such forward – looking statements expressed.

The company’s products under development also PLX – IBD, targeting Inflammatory Bowel Disease , PLX – MS, targeting Multiple Sclerosis; PLX-BMT, targeting the global shortage of matched tissue for bone marrow transplantation by improving transplantation of hematopoietic stem cells contained in umbilical cord blood, and PLX – sTROKE, targeting ischemic stroke.. To improve Pluristem ‘s first product in development, PLX-PAD to of millions of millions of people suffering from peripheral arterial disease .That Microcyn technologies platform has a biocompatible solution to active oxychlorine compounds. These solutions of the Microcyn have derived technological platform shows in a multiplicity of research and empirical tests, the ability to forward-Looking Statements pathogen, including antibiotic-resistant obtain bacterial strains deal, fungi and spores. The technology is also has wound healing in chronic and acute wounds in clinical trials demonstrated research.

Completing enrollment for the phase of II trials a major milestone of Camera unit and Microcyn has out our technology, said Hoji Alimi, chairman and CEO of Oculus Innovative Sciences. The time underlines the success of our strategic orientation of our our U.S. Clinical program for Microcyn. We think that strategy the greatest long-term returning to Camera unit ‘ investor. Do you have a the reporting preliminary upper row information from that trial in first quarter 2008 .

Other Posts From Category "urology":

Related Posts